The use of pharmacoeconomic data in managed care: closing the credibility gap.
According to the author, MCOs rarely incorporate the findings of pharmacoeconomic studies in formulary decision making. As a result, managed care plans fail to examine the costs and cost savings of a new drug across the whole health care continuum, but see only how it directly affects their system. Credible pharmacoeconomic data can be valuable to formulary decision makers, offering them a broader perspective. However, what constitutes credible pharmacoeconomic data?
Lewis
B E
BE
Fallon Clinic, Inc., Worcester, MA, USA.
D003363:Cost Control; D003659:Decision Making, Organizational; D005569:Formularies as Topic; D007373:Interinstitutional Relations; D008329:Managed Care Programs / Q000191:economics / Q000458:organization & administration*; D009937:Organizational Objectives; D014481:United States